Retatrutide / MOTS-c
Blend of retatrutide (triple incretin agonist) and MOTS-c (mitochondrial-derived peptide), studied for metabolic and body-composition research.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on Retatrutide / MOTS-c. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Pairs triple incretin agonism (retatrutide) with mitochondrial signaling (MOTS-c); studied for metabolic and body-composition effects.
Retatrutide tells your body to release fat from storage and want less food by acting on three hormone receptors at once, while MOTS-c helps your cells actually burn that released fat by activating the cellular energy sensor AMPK inside muscle mitochondria.
Reported side effects
Retatrutide commonly causes nausea (reported in roughly 38-43% of trial participants at higher doses), and adding MOTS-c alongside AMPK-activating agents like metformin can cause unexpectedly low blood glucose.
Who should avoid it
People subject to WADA anti-doping rules should avoid this stack because MOTS-c is prohibited, and anyone using metformin or berberine should be especially cautious due to additive blood-glucose-lowering effects.
What gets monitored
Glucose response monitoring is named: the page states to test glucose response carefully in the early weeks if metformin or berberine is used alongside MOTS-c. A blood test (SiPhox Health At-Home Blood Test) is listed as a recommended supply. [Source: peptidedosingprotocols.com]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Retatrutide / MOTS-c or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Retatrutide: titrate 1 → 2 → 4 → 6 → 9 mg weekly (maintenance 9 mg or 12 mg weekly); MOTS-c intermittent: 5 mg 2-3x weekly (maintenance 5-10 mg 2-3x weekly); MOTS-c low-dose daily alternative: start 200 mcg/day up to 1 mg/day | Retatrutide: once weekly; MOTS-c: 2-3x weekly (intermittent) or daily (low-dose alternative)Conservative starter: retatrutide weeks 1-24, MOTS-c weeks 5-12 then off; Standard research cycle: retatrutide weeks 1-48, MOTS-c 8-week pulses with 4-week breaks; Aggressive deficit: retatrutide weeks 1-68, MOTS-c 6 weeks on / 2 weeks off repeating | subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
- Retatrutide: once weekly; MOTS-c: 2-3x weekly (intermittent) or daily (low-dose alternative)Conservative starter: retatrutide weeks 1-24, MOTS-c weeks 5-12 then off; Standard research cycle: retatrutide weeks 1-48, MOTS-c 8-week pulses with 4-week breaks; Aggressive deficit: retatrutide weeks 1-68, MOTS-c 6 weeks on / 2 weeks off repeating
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com]
- Standard 7-Step Reconstitution: (1) Let the lyophilized vial and BAC water reach room temperature before opening. (2) Swab both vial stoppers with alcohol and let them dry. (3) Pull the planned BAC water volume into a sterile syringe. (4) Inject the BAC water slowly down the inside of the vial wall, do not aim at the powder. (5) Swirl or roll gently until fully dissolved; do not shake. (6) Confirm the solution is clear; label the vial with compound name, concentration, and date. (7) Store at 2-8 °C; use retatrutide within 28-60 days and MOTS-c within 7 days for best potency. Each compound is reconstituted separately. Retatrutide common concentration: 10 mg vial + 1.0 mL BAC water = 10 mg/mL. MOTS-c common concentration: 10 mg vial + 2.0 mL BAC water = 5 mg/mL. MOTS-c aliquots may be stored at -20 °C for 2-3 months.
Common questions
Can you take MOTS-c with retatrutide?
Yes, but do not start both on the same day. Standard community protocols run retatrutide alone for the first 4 weeks at 1 mg weekly to confirm GI tolerance, then add MOTS-c at Week 5. The compounds use different mechanisms, so there are no known direct interactions, but both lower blood glucose, so monitor carefully if you also use metformin, berberine, or train fasted.
How much MOTS-c should I take with retatrutide?
Two common approaches. The intermittent approach uses 5–10 mg of MOTS-c, 2–3 times per week, usually on training days. The low-dose daily approach starts at 200 mcg per day and steps up to about 1 mg per day. Most community protocols use the intermittent approach because MOTS-c stays active in the AMPK pathway for roughly 72 hours per injection.
What is the recommended dose when taking MOTS-c with retatrutide?
Retatrutide is titrated from 1 mg up by 4-week steps (1 → 2 → 4 → 6 → 9 mg), with 12 mg as the maximum tested dose. MOTS-c is added at Week 5 at 5 mg, 2–3 times per week.
Is there a pre-blended retatrutide + MOTS-c vial?
No. As of June 2026, no commercial supplier offers retatrutide and MOTS-c in a single pre-blended vial. The two compounds have very different reconstituted-stability windows—MOTS-c is only stable for about 7 days at 2–8 °C, while retatrutide stays stable for 28–60 days—which makes a pre-blend impractical. Use separate vials.
How do you reconstitute the retatrutide + MOTS-c stack?
Reconstitute each compound separately with bacteriostatic water. A 10 mg retatrutide vial with 1 mL BAC water gives 10 mg/mL (a 4 mg dose = 40 units on a U-100 syringe). A 10 mg MOTS-c vial with 1 mL BAC water gives 10 mg/mL (a 5 mg dose = 50 units). Inject the BAC water slowly down the inside of the glass, roll gently, never shake. Refrigerate both vials right after reconstitution.
Open the reconstitution calculator →Does MOTS-c help with muscle loss on retatrutide?
This is the main reason researchers pair them. Preclinical evidence links MOTS-c to reduced myostatin signaling. MOTS-c also activates AMPK in muscle and improves mitochondrial function, which supports training capacity when calories are low. No human trial has confirmed this for retatrutide protocols specifically—the case is mechanistic plus community observation.
Is the retatrutide + MOTS-c stack safe?
Each compound has been studied on its own, but the combination has not been tested in any trial. Retatrutide's TRIUMPH-4 trial reported nausea in 38.1–43.2% of participants, dysesthesia in 8.8–20.9% (dose-dependent), and discontinuation rates of 12.2–18.2%. MOTS-c safety data is limited to animal studies and the CB4211 analog Phase 1 trial. The main combined concerns are amplified hypoglycemia risk, GI tolerance, and the standard contamination risk of using two grey-market compounds.
How long should I run the retatrutide + MOTS-c stack?
Retatrutide is run open-ended in clinical trials—TRIUMPH-4 lasted 68 weeks. MOTS-c is usually cycled: 4–8 weeks on, 2–4 weeks off, repeated through the retatrutide cycle. Most community protocols run the combined stack for 16–24 weeks before evaluating results and either continuing, tapering, or moving to maintenance.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for Retatrutide / MOTS-c as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Blend of cagrilintide (amylin analog) and retatrutide (triple GLP-1/GIP/glucagon agonist), studied for weight management.
Blend of cagrilintide (amylin analog) and tirzepatide (GIP/GLP-1 dual agonist), studied for weight management.
Investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), studied once weekly for weight management.
Investigational GLP-1 and glucagon receptor dual agonist studied for weight management and metabolic health.
Investigational triple GLP-1 / GIP / glucagon receptor agonist studied for weight management.
Semaglutide is one of the most widely studied weight-loss and diabetes drugs in the world.